# Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

> **NCT02766465** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 138 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **DRUG:** r-ATG
- **PROCEDURE:** Hematopoietic Cell Transplant
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **PROCEDURE:** Standard of Care
- **DRUG:** Alemtuzumab
- **DRUG:** Total Body Irradiation (TBI)
- **DRUG:** Sirolimus
- **DRUG:** Melphalan
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT02766465
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-16
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-08-02
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02766465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02766465, "Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02766465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*